EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infections

Abdullah T Aslan, Yukiko Ezure, Elif Seren Tanriverdi, Osman Dağ, Cansu Cimen, Ayşe Kaya Kalem, Bircan Kayaaslan, Sevil Alkan, Bahadır Köylü, Emine Büşra Ata, Bilge Çağlar, Neşe Saltoğlu, Uğur Önal, Seçil Deniz, Onur Ural, Murtaza Öz, Mehmet Bakir, Mesut Yilmaz, Rümeysa Çakmak, Ayşe Batirel, Özlem Akdoğan, Nurcan Baykam, Çiğdem Erol, Tuğba Yanik-Yalçin, Oya Özlem Eren-Kutsoylu, Zeynep Türe-Yüce, Gamze Kalin-Ünüvar, Zuhal Özer-Şimşek, Seda Güzeldağ, Adem Köse, Mustafa Cihangiroğlu, Dilek Yağci-Caglayik, Muhammed Burak Sevinç, Zerrin Aktaş, Oral Öncül, Gülden Ersöz, Ayşe Sesin Kocagöz, Gülşen Hazirolan, Tuğçe Ünalan-Altintop, Bedia Dinç

Journal of Antimicrobial Chemotherapy · 2026-05-05 · 81 (6)

DOI: 10.1093/jac/dkag161 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Delays in appropriate antimicrobial therapy can increase the risk of all-cause mortality (ACM) in hospital-acquired bloodstream infections (HA-BSIs) caused by Gram-negative bacteria (GNB). We aimed to evaluate the effectiveness of early appropriate antimicrobial therapy (EAAT) compared with late appropriate antimicrobial therapy (LAAT) in this population. Methods This study used data from a multi-centre, prospective cohort including adult patients with HA-BSI caused by GNB across 22 Turkish hospitals. A hypothetical target trial allocating participants with HA-BSI caused by monobacterial GNB to either EAAT or LAAT was emulated using the weighting approach. The primary outcome was 14 day ACM; 28 day ACM was a secondary outcome. Cox proportional hazards models with inverse probability weighting were applied to account for confounding, with antibiotic treatment incorporated as a time-dependent variable. Results Among 680 patients, 14 day ACM occurred in 14.7% (40/272) of the EAAT group and 42.9% (175/408) of the LAAT group. EAAT was associated with a lower risk of 14 day ACM [adjusted hazard ratio (aHR) = 0.41; 95% CI: 0.28–0.61). Similarly, 26.1% (71/272) of the patients treated with EAAT and 49.5% (202/408) of those receiving LAAT died during 28 day follow-up (aHR = 0.66; 95% CI: 0.50–0.86). In the carbapenem-resistant GNB subset, EAAT reduced the hazard of 14 day ACM (aHR = 0.36; 95% CI: 0.21–0.60) and 28 day ACM (aHR = 0.60; 95% CI: 0.44–0.84). All prespecified and post hoc analyses consistently supported these findings. Conclusions EAAT was associated with a survival benefit in individuals with HA-BSI due to GNB. Although these findings support early initiation of appropriate therapy, residual confounding cannot be excluded.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →